Development of a codrug approach for sustained drug delivery across microneedle-treated skin

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1458-1467

  Ghosh, Priyanka ^a,c   Pinninti, Raghotham R ^a,d   Hammell, Dana C ^a,b   Paudel, Kalpana S ^a,e   Stinchcomb, Audra L ^a,b,c  

^a University of Kentucky   (United States)

^b AllTranz Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d HDH Pharma Inc   (United States)

^e South College School of Pharmacy   (United States)

Author keywords

Codrug; Cyclooxygenase inhibitor; Metabolism; Microneedle; Naltrexone; Permeability; Pore closure; Preformulation; Stability; Transdermal

Indexed keywords

DICLOFENAC; NALTREXONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; EPIDERMIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MICRONEEDLE; NONHUMAN; PH; PHYSICAL CHEMISTRY; SKIN; SUSTAINED DRUG RELEASE; VISCOSITY;

EID: 84876317295     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23469     Document Type: Article

References (49)

1. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115-124.
2. Prausnitz MR, Langer R. 2008. Transdermal drug delivery. Nat Biotech 26:1261-1268.
3. Strasinger CL, Scheff NN, Stinchcomb AL. 2008. Prodrugs and codrugs as strategies for improving percutaneous absorption. Expert Rev Dermatol 3:221-233.
4. Prausnitz MR. 2004. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581-587.
5. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, Prausnitz MR. 2001. Lack of pain associated with microfabricated microneedles. Anesth Analg 92:502-504.
6. Gill HS, Denson DD, Burris BA, Prausnitz MR. 2008. Effect of microneedle design on pain in human volunteers. Clin J Pain 24:585-594 10.1097/AJP.0b013e31816778f9.
7. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. 1992. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 49:881-887.
8. Swift RM. 1999. Medications and alcohol craving. NIAAA 23:207.
9. Lee Y, Park S, Kim Y, Kim D, Jeong J, Myrick H, Kim Y. 2005. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol 40:297-301.
10. Swift R. 2010. Medications acting on the dopaminergic system in the treatment of alcoholic patients. Curr Pharm Des 16:2136-2140.
11. Hulse GK, Basso MR. 2000. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev 19:41-48.
12. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. 1997. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry 54:737-742.
13. PDR. 1996. 2nd ed., New Jersey: Medical economics.
14. Alkermes Vivitrol (naltrexone for extended release injectable suspension). http://www.vivitrol.com/.
15. Alkermes. Vivitrol, Administration and Dosing. http://www.vivitrol.com/hcpadmin/administration.
16. McCaul ME, Wand GS, Rohde C, Lee SM. 2000. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol: Clin Exp Res 24:1385-1391.
17. Covey LS, Glassman AH, Stetner F. 1999. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18:31-40.
18. Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. 2004. A duplex "Gemini" prodrug of naltrexone for transdermal delivery. J Control Release 97:283-290.
19. Haranath KV, Mohamed OH, Jianhong C, Stan LB, Peter AC, Audra LS. 2005. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharm Res 22:758-65.
20. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. 2008. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci: Off J Eur Fed Pharm Sci 33:371-379.
21. Banks S, Pinninti R, Gill H, Crooks P, Prausnitz M, Stinchcomb A. 2008. Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res 25:1964-1964.
22. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. 2008. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci 105:2058-2063.
23. Verebey K, Volavka J, Mule SJ, Resnick RB. 1976. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20:315-328.
24. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. 2010. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci 99:3072-3080.
25. Kalluri H, Banga A. 2011. Formation and closure of microchannels in skin following microporation. Pharm Res 28:82-94.
26. Feingold K. 2002. Regulation of permeability barrier homeostasis. J Invest Dermatol 119:986-986.
27. Feingold KR, Schmuth M, Elias PM. 2007. The regulation of permeability barrier homeostasis. J Invest Dermatol 127:1574-1576.
28. Menon GK, Feingold KR, Elias PM. 1992. Lamellar body secretory response to barrier disruption. J Invest Dermatol 98:279-289.
29. Grubauer G, Elias PM, Feingold KR. 1989. Transepidermal water loss: The signal for recovery of barrier structure and function. J Lipid Res 30:323-33.
30. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. 2007. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 156:25-33.
31. Davidson JM, Breyer MD. 2003. Inflammatory modulation and wound repair. J Invest Dermatol 120:11-12.
32. Muller-Decker K, Hirschner W, Marks F, Furstenberger G. 2002. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 119:1189-1195.
33. Futagami A, Ishizaki M, Fukuda Y, Kawana S, Yamanaka N. 2002. Wound healing involves induction of cyclooxygenase-2 expression in rat skin. Lab Invest 82:1503-1513.
34. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. 1994. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacology Exp Ther 271:927-934.
35. Banks S, Paudel K, Brogden N, Loftin C, Stinchcomb A. 2011. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res 28(5)2011-9.
36. Schmid-Wendtner MH, Korting HC. 2006. The pH of the skin surface and its impact on the Barrier Function. Skin Pharmacol Physiol 19:296-302.
37. Vaddi HK, Banks SL, Chen J, Hammell DC, Crooks PA, Stinchcomb AL. 2009. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J Pharm Sci 98:2611-2625.
38. Prusakiewicz J, Ackermann C, Voorman R. 2006. Comparison of skin esterase activities from different species. Pharm Res 23:1517-1524.
39. Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C, Landsiedel R. 2007. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 39:659-698.
40. Scifinder® Copyright © 2012 American Chemical Society. https://scifinder.cas.org.
41. Milewski M, Stinchcomb A. 2011. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res 28:124-134.
42. Roberts ME, Mueller KR. 1990. Comparisons of in vitro nitroglycerin (TNG) flux across yucatan pig, hairless mouse, and human skins. Pharm Res 7:673-676.
43. MICROMEDEX® 1.0 (Healthcare Series). http://www.micromedex.com.
44. Gelfuso GM, Gratieri T, Souza JG, Thomazine JA, Lopez RFV. 2011. The influence of positive or negative charges in the passive and iontophoretic skin penetration of porphyrins used in photodynamic therapy. Eur J Pharm Biopharm 77:249-256.
45. Barbero AM, Frasch HF. 2009. Pig and guinea pig skin as surrogates for human in vitro penetration studies: A quantitative review. Toxicol In Vitro 23:1-13.
46. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. 2005. Transdermal delivery of naltrexone and its active metabolite 6-β-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci 94:1965-1975.
47. Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. 2010. In Vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release 146:37-44.
48. Milewski M. 2012. Microneedle-assisted transdermal delivery of naltrexone species: in vitro permeation and in vivo pharmacokinetic Studiesuniversity of Kentucky Doctoral Dissertations. Paper 160. http://uknowledge.uky.edu/gradschool_diss/160.
49. Milewski M, Pinninti RR, Stinchcomb AL. 2012. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin. J Pharm Sci 101:2777-2786.